Biosimilar erythropoietin in anemia treatment (BEAT)—Efficacy and safety of a 1:1 dose conversion from EPREX(®) to EPIAO(®) in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study

EPREX(®)/ERYPO(®)/PROCRIT(®) (epoetin alfa, Janssen-Cilag GmbH) was the first available recombinant human erythropoietin (rHuEPO) and was universally reference product as per the recommendation provided by European Medicines Agency. EPIAO(®) is a biosimilar formulation of EPREX(®), and making it a 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Bolong, Isachkina, Alina Nikolaevna, Shutov, Evgeny Viktorovich, Selyutin, Alexander Alekseevich, Kvitkova, Lyudmila Vladimirovna, Shilo, Valery Yuryevich, Vetchinnikova, Olga Nikolaevna, Alexandrov, Ilya Vyacheslavovich, Perlin, Dmitry Vladislavovich, Zuev, Alexander Vasilievich, Davydkin, Igor Leonidovich, Mironova, Tatyana Pavlovna, Solovyova, Olga Mikhailovna, Tutin, Alexey Pavlovich, Omelchenko, Alexey Mikhailovich, Vareesangthip, Kriengsak, Khadikova, Nadezhda Georgievna, Li, Man, Li, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704908/
https://www.ncbi.nlm.nih.gov/pubmed/36451454
http://dx.doi.org/10.1097/MD.0000000000031426

Ejemplares similares

Ejemplares similares